Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T Cell Therapy and HER2/neu Vaccine in Advanced HER2+ Breast Cancer
NCT00791037Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2008
- Primary completion
- Jul 2013
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ex vivo-expanded HER2-specific T cells in breast cancer, sponsored by University of Washington. Started Oct 2008; status: completed.
02
Drugs
ex vivo-expanded HER2-specific T cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00791037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791037.